Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7436 (aprepitant) Phase 3 study for prevention of chemotherapy-induced nausea and vomiting in adolescents
jRCT2080220825Phase 3
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Ono Pharmaceutical.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCT2080220825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220825.